Prevention of Venous Thromboembolism during Pregnancy and the Puerperium with a Special Focus on Women with Hereditary Thrombophilia or Prior VTE-Position Paper of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH).


Journal

Hamostaseologie
ISSN: 2567-5761
Titre abrégé: Hamostaseologie
Pays: Germany
ID NLM: 8204531

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 27 6 2020
medline: 12 8 2021
entrez: 27 6 2020
Statut: ppublish

Résumé

Venous thromboembolism (VTE) is a major cause of maternal morbidity during pregnancy and the postpartum period. Because there is a lack of adequate study data, management strategies for the prevention of VTE during pregnancy have mainly been deduced from case-control and observational studies and extrapolated from recommendations for non-pregnant patients. The decision for or against pharmacologic thromboprophylaxis must be made on an individual basis weighing the risk of VTE against the risk of adverse side effects such as severe bleeding complications. A comprehensive, multidisciplinary approach is often essential as the clinical scenario is made more complex by the specific obstetric context, especially in the peripartum period. As members of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH), we summarize the evidence from the available literature and aim to establish a more uniform strategy for VTE risk assessment and thromboprophylaxis in pregnancy and the puerperium. In this document, we focus on women with hereditary thrombophilia, prior VTE and the use of anticoagulants that can safely be applied during pregnancy and the lactation period.

Identifiants

pubmed: 32590872
doi: 10.1055/a-1132-0750
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

572-590

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Christina Hart (C)

Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.

Rupert Bauersachs (R)

Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany.
Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany.

Ute Scholz (U)

MVZ Labor Dr. Reising-Ackermann und Kollegen, Zentrum für Blutgerinnungsstörungen, Leipzig, Germany.

Rainer Zotz (R)

Centrum für Blutgerinnungsstörungen und Transfusionsmedizin, Düsseldorf, Germany.

Frauke Bergmann (F)

MVZ Wagnerstibbe, Amedes-Gruppe, Hannover, Lower Saxony, Germany.

Hannelore Rott (H)

Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany.

Birgit Linnemann (B)

Division of Angiology, University Center of Vascular Medicine, University Hospital Regensburg, Regensburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH